Emerging pipeline drugs for hepatitis B infection

Bibliography

• Hepatitis B vaccines: WHO position paper. WHO Wkly Epidemiol Rec 2009;84:405-20
   PubMedGoogle Scholar
• Perz JF, Armstrong GL, Farrington LA, The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-38
   PubMed Web of Science ®Google Scholar
• Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 2003;39(Suppl 1):S64-9
   PubMedGoogle Scholar
• Liu Y, Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect 2010;118:818-24
   PubMed Web of Science ®Google Scholar
• Yang HI, Lu SN, Liaw YF, Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-74
   PubMed Web of Science ®Google Scholar
• Fwu CW, Chien YC, Kirk GD, Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study. J Natl Cancer Inst 2009;101:1019-27
   PubMed Web of Science ®Google Scholar
• Wong GL, Wong VW, Choi PC, Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients. Clin Gastroenterol Hepatol 2009;7:227-33
   PubMed Web of Science ®Google Scholar
• Niederau C, Heintges T, Lange S, Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-7
   PubMed Web of Science ®Google Scholar
• Chen CJ, Yang HI, Su J, Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73
   PubMed Web of Science ®Google Scholar
• Liu J, Lee M H, Batrla-Utermann R, Quantitative hepatitis B surface antigen levels are significant independent predictors of HBV DNA and HBsAG seroclearance in chronic hepatitis B. Hepatology 2011;54:480A
   Web of Science ®Google Scholar
• Levrero M, Pollicino T, Petersen J, Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009;51:581-92
   PubMed Web of Science ®Google Scholar
• Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004;10:S74-85
   PubMed Web of Science ®Google Scholar
• Simonetti J, Bulkow L, McMahon BJ, Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010;51:1531-7
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2
   PubMed Web of Science ®Google Scholar
• EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42
   PubMed Web of Science ®Google Scholar
• Sun X, Qin W, Zhou R, Effect of conventional interferon-alpha in patients with HBeAg-positive chronic hepatitis B: a systematic review and meta-analysis. J Evid Based Med 2010;3:220-5
   Google Scholar
• Cooksley WG, Piratvisuth T, Lee SD, Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10:298-305
   PubMed Web of Science ®Google Scholar
• Yu HB, Liu EQ, Lu SM, Zhao SH. Treatment with peginterferon versus interferon in Chinese patients with hepatitis B. Biomed Pharmacother 2010;64:559-64
   PubMed Web of Science ®Google Scholar
• Lau GK, Piratvisuth T, Luo KX, Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95
   PubMed Web of Science ®Google Scholar
• Marcellin P, Lau GK, Bonino F, Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-17
   PubMed Web of Science ®Google Scholar
• Janssen HL, van Zonneveld M, Senturk H, Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-9
   PubMed Web of Science ®Google Scholar
• Liaw Y, Xie Q, Han K, Shorter duration and lower dose of peginterferon alfa-2a thereapy results in inferior HBeAg seroconversion rates compared with the duration and dose of 48 weeks and 180 muG: Neptune study. Hepatology 2010;52:429A
   Web of Science ®Google Scholar
• Dienstag JL, Schiff ER, Wright TL, Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63
   PubMed Web of Science ®Google Scholar
• Liaw YF, Leung NW, Chang TT, Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-80
   PubMed Web of Science ®Google Scholar
• Leung NW, Lai CL, Chang TT, Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32
   PubMed Web of Science ®Google Scholar
• Lok AS, Lai CL, Leung N, Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-22
   PubMed Web of Science ®Google Scholar
• Puchhammer-Stockl E, Mandl CW, Kletzmayr J, Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy. J Infect Dis 2000;181:2063-6
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG, Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7
   PubMed Web of Science ®Google Scholar
• Lampertico P, Vigano M, Facchetti F, Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B. Nephrol Dial Transplant 2011;26:2037-41
   PubMed Web of Science ®Google Scholar
• Chang TT, Gish RG, de Man R, A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Rose RE, Baldick CJ, Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-14
   PubMed Web of Science ®Google Scholar
• Lai CL, Shouval D, Lok AS, Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20
   PubMed Web of Science ®Google Scholar
• Chang TT, Chao YC, Gorbakov VV, Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat 2009;16:784-9
   PubMed Web of Science ®Google Scholar
• Colonno RJ, Rose R, Baldick CJ, Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006;44:1656-65
   PubMed Web of Science ®Google Scholar
• Chang TT, Gish RG, Hadziyannis SJ, A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005;129:1198-209
   PubMed Web of Science ®Google Scholar
• Lange CM, Bojunga J, Hofmann WP, Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009;50:2001-6
   PubMed Web of Science ®Google Scholar
• Damerow H, Yuen L, Wiegand J, Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern. J Med Virol 2010;82:1850-8
   PubMed Web of Science ®Google Scholar
• Lai CL, Gane E, Liaw YF, Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-88
   PubMed Web of Science ®Google Scholar
• Liaw YF, Gane E, Leung N, 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-95
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Gane E, Liaw YF, Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009;51:11-20
   PubMed Web of Science ®Google Scholar
• Goncalves J, Laeufle R, Avila C, Increased risk with combination of telbivudine and pegylated-interferon Alfa-2A in study CLDT600A2406, compared to uncommon rate with telbivudine monotherapy from Novartis Global Database. J Hepatol 2009;50:S329-30
   Web of Science ®Google Scholar
• Garcia G, Smith CI, Weissberg JI, Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B. A randomized, double-blinded, placebo-controlled trial. Ann Intern Med 1987;107:278-85
   PubMed Web of Science ®Google Scholar
• Marcellin P, Buti M, Gane EJ, Five Years of Treatment with Tenofovir DF (TDF) for Chronic Hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. Hepatology 2011;54:1011A
   Web of Science ®Google Scholar
• Sheldon J, Camino N, Rodes B, Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005;10:727-34
   PubMed Web of Science ®Google Scholar
• Verhelst D, Monge M, Meynard JL, Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002;40:1331-3
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Yurdaydin C, Dalekos GN, Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011;364:322-31
   PubMed Web of Science ®Google Scholar
• Piccolo P, Lenci I, Demelia L, A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther 2009;14:1165-74
   PubMed Web of Science ®Google Scholar
• Wursthorn K, Lutgehetmann M, Dandri M, Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006;44:675-84
   PubMed Web of Science ®Google Scholar
• Marcellin P, Martinot-Peignoux M, Lapalus M, High rate of HBsAg loss predicted by baseline HBsAg titer and decline on treatment in chronic hepatitis B patients receiving pegylated interferon plus tenofovir combination therapy. Hepatology 2011;54:1010A
   Web of Science ®Google Scholar
• Sarin SK, Sood A, Kumar M, Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 2007;102:96-104
   PubMed Web of Science ®Google Scholar
• Ning Q, Han M, Sun Y, Patients with HBeAg-Positive Chronic Hepatitis B (CHB) with a maintained virological response to entecavir acheived HBsAg clearance when switched to peginterferon Alfa-2A therapy (OSST Study). Hepatology 2011;54:1010A
   Web of Science ®Google Scholar
• Ouzan D, Guillaume P, Joly H, Add-on peg-interferon to a stable nucleoside regimen led to loss of HBsAg in chronic HBeAg negative patients. Hepatology 2011;54:1015A
   Web of Science ®Google Scholar
• Lai CL, Leung N, Teo EK, A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-36
   PubMed Web of Science ®Google Scholar
• Carey I, Harrison PM. Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs 2009;18:1655-66
   PubMed Web of Science ®Google Scholar
• Wiegand J, Wedemeyer H, Finger A, A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels. Antivir Ther 2008;13:547-54
   PubMed Web of Science ®Google Scholar
• Brunetto MR, Moriconi F, Bonino F, Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009;49:1141-50
   PubMed Web of Science ®Google Scholar
• Rijckborst V, Hansen BE, Cakaloglu Y, Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010;52:454-61
   PubMed Web of Science ®Google Scholar
• Moucari R, Mackiewicz V, Lada O, Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151-7
   PubMed Web of Science ®Google Scholar
• Tziomalos K. Effect of antiviral treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis B. World J Hepatol 2010;2:91-3
   PubMedGoogle Scholar
• Zhang QQ, An X, Liu YH, Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Virol J 2011;8:72
   PubMed Web of Science ®Google Scholar
• Liaw YF, Sung JJ, Chow WC, Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31
   PubMed Web of Science ®Google Scholar
• Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011;54:91-100
   PubMed Web of Science ®Google Scholar
• Leung N, Gish RG, Wang C, A randomized, double-blind comparison of 3 doses of emtricitabine in patients with chronic hepatitis B given 48 weeks of treatment. Hepatology 2001;34:349A
   Web of Science ®Google Scholar
• Yoo BC, Kim JH, Chung YH, Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007;45:1172-8
   PubMed Web of Science ®Google Scholar
• Lau GK, Leung N. Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study. Korean J Hepatol 2010;16:315-20
   PubMedGoogle Scholar
• Seigneres B, Pichoud C, Martin P, Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 2002;36:710-22
   PubMed Web of Science ®Google Scholar
• Yuen MF, Kim J, Kim CR, A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. Antivir Ther 2006;11:977-83
   PubMed Web of Science ®Google Scholar
• Yuen MF, Han KH, Um SH, Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. Hepatology 2010;51:767-76
   PubMed Web of Science ®Google Scholar
• Lai C, Ahn S, Lee K, A phase IIB study of the efficacy and safety of LB80380 vs entecavir in treatment-naive patients with chronic hepatitis B. J Hepatol 2011;54:S535-46
   Web of Science ®Google Scholar
• Michalak TI, Zhang H, Churchill ND, Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis B. Antimicrob Agents Chemother 2009;53:3803-14
   PubMed Web of Science ®Google Scholar
• Lee HW, Lee JI, Um SH, Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: A prospective randomized, comparative pilot study. J Gastroenterol Hepatol 2008;23:729-35
   PubMed Web of Science ®Google Scholar
• Yang YF, Zhao W, Zhong YD, Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis. Antiviral Res 2008;77:136-41
   PubMed Web of Science ®Google Scholar
• Wu GY, Zheng XJ, Yin CC, Inhibition of hepatitis B virus replication by Bay 41-4109 and its association with nucleocapsid disassembly. J Chemother 2008;20:458-67
   PubMed Web of Science ®Google Scholar
• Stray SJ, Zlotnick A. BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly. J Mol Recognit 2006;19:542-8
   PubMed Web of Science ®Google Scholar
• Schieck A, Muller T, Schulze A, Solid-phase synthesis of the lipopeptide Myr-HBVpreS/2-78, a hepatitis B virus entry inhibitor. Molecules 2010;15:4773-83
   PubMed Web of Science ®Google Scholar
• Petersen J, Dandri M, Mier W, Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008;26:335-41
   PubMed Web of Science ®Google Scholar
• Gaur AH, Bagga B, Barman S, Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N Engl J Med 2010;362:88-9
   PubMed Web of Science ®Google Scholar
• Troia-Cancio P, Asmuth DM. Lessons from maraviroc clinical trials. Expert Rev Anti Infect Ther 2011;9:649-51
   PubMed Web of Science ®Google Scholar
• Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet 2011;378:73-85
   PubMed Web of Science ®Google Scholar
• Lutgehetmann M, Petersen J, Volz T, The entry inhibitor Myrcludex-B efficiently blocks viral spreading in vivo in human liver Chimeric UPA/SCID mice previously infected with hepatitis B virus. Hepatology 2011;54:372A
   PubMed Web of Science ®Google Scholar
• Al-Mahtab M, Bazinet M, Vaillant A. REP 9AC is a potent HBsAg release inhibitor which clears serum HBsAg and elicits svrs in patients with chronic hepatitis B. J Hepatol 2011;54:S34
   PubMed Web of Science ®Google Scholar
• Bock CT, Tillmann HL, Maschek HJ, A preS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly. Gastroenterology 1997;113:1976-82
   PubMed Web of Science ®Google Scholar
• Noordeen F, Vaillant A, Juteau JM, Preclinical development of the amphipathic DNA polymer REP 9AC for the treatment of HBV infection. Global Antivir J 2007;3:26
   Google Scholar
• Menne S, Tennant B, Liu KH, Anti-viral efficacy and induction of an antibody response against surface antigen with the TLR7 agonist GS-9620 in the woodchuck model of chronic HBV infection. J Hepatol 2011;54:S441
   Web of Science ®Google Scholar
• Lanford R, Guerra B, Chavez D, Therapeutic efficacy of the TLR7 agonist GS-9620 for HBV chronic infection in chimpanzees. 46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011). Berlin. March 30-April 3. Abstract 384
   Google Scholar
• Vicari AP, Schmalbach T, Lekstrom-Himes J, Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. Antivir Ther 2007;12:741-51
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Bacon BR, Gordon SC, Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 2007;46:1341-9
   PubMed Web of Science ®Google Scholar
• Korba BE, Montero AB, Farrar K, Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res 2008;77:56-63
   PubMed Web of Science ®Google Scholar
• Stachulski AV, Pidathala C, Row EC, Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication. J Med Chem 2011;54:4119-32
   PubMed Web of Science ®Google Scholar
• Parvez MK, Sehgal D, Sarin SK, Inhibition of hepatitis B virus DNA replicative intermediate forms by recombinant interferon-gamma. World J Gastroenterol 2006;12:3006-14
   PubMed Web of Science ®Google Scholar
• Carreno V, Moreno A, Galiana F, Bartolome FJ. Alpha- and gamma-interferon versus alpha-interferon alone in chronic hepatitis B. A randomized controlled study. J Hepatol 1993;17:321-5
   PubMed Web of Science ®Google Scholar
• Keeffe EB, Zeuzem S, Koff RS, Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007;5:890-7
   PubMed Web of Science ®Google Scholar
• Lui YY, Tsoi KK, Wong VW, Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. Antivir Ther 2010;15:145-55
   PubMed Web of Science ®Google Scholar
• Feld JJ, Wong DK, Heathcote EJ. Endpoints of therapy in chronic hepatitis B. Hepatology 2009;49:S96-S102
   PubMed Web of Science ®Google Scholar
• Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008;359:1486-500
   PubMed Web of Science ®Google Scholar
• Marcellin P, Buti M, Krastev Z, A randomized, double-blind, comparison of Tenofovir DF (TDF) versus Adefovir Diolvoxil (ADV) for the treatment of HBeAg-negative Chronic Hepatitis B (CHB): Study GS-US-174 0102. Hepatology 2007;46:290A
   Web of Science ®Google Scholar
• Marcellin P, Brunetto M, Bonino F, Long-term Follow-up of HBsAg clearance in patients with HBeAG-negative CHB treated with PEG-Interferon Alfa-2a: increase in HBsAg clearance rate from 3% 6 months post-treatment to 8% after 3 years. Hepatology 2007;46:673A
   Web of Science ®Google Scholar
• Heathcote EJ, Gane E, DeMan R, A Randomized, double-blind, comparison of Tenofovir DF (TDF) versus Adefovir Dipivoxil (ADV) for the treatment of HBeAg positive Chronic Hepatitis B (CHB): Study GS-US-174-0103. Hepatology 2007;46:861A
   PubMed Web of Science ®Google Scholar
• Lai CL, Gane E, Liaw YF, Telvibudine (LDT) vs. lamivudine for Chronic Hepatitis B: first-year results from the international phase III globe trial. Hepatology 2005;42:748A
   PubMed Web of Science ®Google Scholar